3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
NET
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
3
Thyroid Neoplasms
2
Brain Neoplasms
2
Thyroid Cancer, Papillary
1
Thoracic Neoplasms
1
Sarcoma
1
Salivary Gland Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms by Site
1
Neoplasms
1
Melanoma
1
Lymphoma, Large-Cell, Anaplastic
1
Lung Neoplasms
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Digestive System Neoplasms
1
Digestive System Diseases
1
Colorectal Neoplasms
1
Colonic Diseases
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Bronchogenic
1
Bronchial Neoplasms
1
Interventions
Carboplatin
44
Paclitaxel
43
liposomal doxorubicin
23
Topotecan
19
Gemcitabine
18
pembrolizumab
17
Cyclophosphamide
17
Bevacizumab
16
Cisplatin
12
niraparib
9
olaparib
8
fludarabine
7
Taxes
7
Docetaxel
7
aldesleukin
6
Nivolumab
6
Doxorubicin
6
1-dodecylpyridoxal
6
oregovomab
5
fludarabine phosphate
5
Peripheral Blood Stem Cell Transplantation
5
Filgrastim
5
rucaparib
4
durvalumab
4
avelumab
4
Surgical Procedures, Operative
4
Melphalan
4
Ipilimumab
4
Interleukin-2
4
Etoposide
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Ovarian Neoplasms
×
alectinib
×
Clear all
NCT04644315
2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2
Terminated
1 enrolled
5 charts